Cheap Cialis online - Generic and Brand.LOWEST PRICES ONLINE.

Glitches in the BDNF gene cut levels of a brain chemical and may make obesity more likely, report scientists at the National Institutes of Health.

A variant of the TLR3 gene may guard against "dry" age-related macular degeneration, a top cause of vision loss, Chinese and U.S. scientists report.

Using the drug magnesium sulfate to stop preterm labor may make moderate to severe cerebral palsy less likely, new research shows.

When it comes to getting older, is there a point when your mental functions start to wane?

The finding that fat cells from obese people behave differently from those in normal-weight people could help explain how obesity leads to diseases like diabetes.

Children develop altruism and the desire for things to be fair by the time they are 7 or 8, according to a Swiss study.

Six patients taking the type 2 diabetes drug Byetta (exenatide) are now reported to have died after developing pancreatitis.

Will bloodmobiles soon be a thing of the past, like vacuum-tube televisions and glass milk bottles delivered daily?

More important: Will the use of embryonic stem cells, which became a heated issue during the 2004 presidential election, finally produce a breakout product? One that will squelch the controversy for all but a few die-hards who still prefer their milk in glass bottles?

Researchers at Advanced Cell Technology in Worcester, Massachusetts, announced the breakthrough a few days ago. Working with scientists from the Mayo Clinic in Rochester, Minnesota, and the University of Chicago, A.C.T.'s team says it has developed a method for making potentially unlimited and scalable supplies of synthetic blood from embryonic stem cells.

The findings are published in Blood, a scientific journal. A.C.T.'s chief scientific officer Robert Lanza led the team.

If the claim holds up to scrutiny, it would be a huge boon for humankind, which until now has had to collectively open its veins to provide tons of this basic stuff of life for people who need extra blood because of injuries, surgeries or disease.

The discovery also would remove the danger of blood being tainted by pathogens that cause hepatitis, H.I.V. and Creutzfeldt-Jakob disease, among other viruses and bacteria.

But will this promise become reality?

Advanced Cell Technology has made incredible claims before. Under recently departed C.E.O. Michael West—whom some critics compared with the circus promoter P.T. Barnum—the company routinely asserted that stem-cell therapies were likely to reverse the aging process and grow replacement body parts, while most scientists were talking a more cautious line.

The company was the first to clone an endangered species, an Asian bovine called a gaur, which died soon after—possibly from causes unrelated to the cloning. A.C.T. also claimed it had cloned the first human embryo, attracting worldwide attention, though the embryos grew to only a few cells in size.

Some blame the company's over-enthusiasm for playing into the hands of stem-cell opponents in the Bush administration and elsewhere who were bent on squelching this new therapy. President Bush severely restricted federal funding for stem-cell research in 2001—restrictions that remain today, and are likely to until the next administration takes office.

Under Lanza, the company may not have fulfilled all of the promises made by West, but it has produced a string of solid discoveries and observations—though none have proved to be commercially viable. Most recently, Lanza's team has also induced stem cells to grow into retinal cells in eyes.

Creating synthetic blood has proved difficult; decades of efforts have so far been in vain. Several potential products are being tested in human clinical trials, most of them focusing on the critical function that blood plays in transporting oxygen. Other products, however, have been abandoned when they either didn't work, or proved to have dangerous or deadly side effects.

Blood created by stem cells is very similar to the real thing, and may avoid the pitfalls with other, more artificial techniques. If further tests confirm A.C.T.'s discovery—and, critically, show that the process is scalable and affordable—stem-cell blood may make the company more attractive to investors as it desperately seeks cash to carry on.

In July, a filing with the Securities and Exchange Commission revealed that A.C.T. had $17 million in current liabilities, but only $1 million in cash and other current assets, the Boston Globe reported. A.C.T.'s stock has been trading at 6 cents per share, down from $8 per share three years ago.

It's hard to know what the new techniques will cost once scaled up, or what revenues the discovery will bring in; Lanza says that he expects the company to know within two years if the processes will work.

Independent scientists are hopeful that the discovery will pan out. "The problem with relying on donated blood is that there are always shortages," Professor Alex Medvinsky, a blood stem-cell expert at the University of Edinburgh, told the Times of London. "The ability to generate red blood cells in very large numbers would be a very big thing."

Dear Dr. Donohue: I married a man while I was overseas. We now live in the United States. Three months ago, I came down with a herpes infection. My husband is the only man I have ever been with. I questioned him, and he said he had been treated for a sexual infection three years ago but that they never told him what it was. I am despondent, because I so wanted to have children. What can I do?

MONTGOMERY, Ala. -- Alabama, pushed to third in national obesity rankings by deep-fried Southern favorites, is cracking down on state workers who are too fat.